ALX Oncology (ALXO) PT Raised to $100 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts ALXO Hot Sheet
Price: $1.37 +12.30%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Credit Suisse analyst Tiago Fauth raised the price target on ALX Oncology (NASDAQ: ALXO) to $100.00 (from $98.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs upgrades Sirius XM Radio to Buy with $37 target
- Scorpio Tankers (STNG) PT Raised to $105 at Evercore ISI
- Lumentum (LITE) PT Lowered to $1,132 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
